TrialThe journal of headache and pain2022

Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2.

Rami Apelian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.